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ABSTRACT
Graft-versus-host disease (GVHD) is a major cause of transplant-related morbidity and mortality in recipients
of allogeneic hematopoietic stem cell transplantation. As GVHD is mediated predominantly by alloreactive
donor T cells, selective allodepletion from the graft may alleviate GVHD, whereas potentially maintaining
other advantages conferred by donor T cells, such as graft survival, antiviral immunity, and graft-versus-
leukemia effect. In this study, we evaluated the ability of methotrexate, a clinically approved antimetabolite
drug, to deplete alloreactive T cells in HLA-mismatched mixed lymphocyte reactions (MLR).We observed that
methotrexate could inhibit the proliferation of alloreactive T cells in primary in vitro MLR. On reexposure of
methotrexate-treated cells to the same allostimulus, a significant reduction in the alloreactive immune
response was observed, whereas responses to third-party allostimuli and viral antigens were preserved. Thus,
our results provide preclinical evidence that in vitro methotrexate treatment results in specific allodepletion
and may be used as an effective agent for preventing GVHD.
© 2007 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) is used for treatment of leukemias and
ther hematopoietic disorders. Graft-versus-host-
isease (GVHD) is a major complication of such
ransplants, leading to considerable morbidity and
ortality [1,2]. Treatment of GVHD requires immu-
osuppression leading to poor immune reconstitution,
isk of infection, and prolonged recovery [3-5].
Although the pathogenesis of GVHD is multifac-
orial, its initiation depends on the presence of allo-
eactive donor T cells in the graft [6-10]. However, T
ells cannot be completely eliminated from the graft
ecause they are required for early engraftment
11,12], immune recovery [13,14], and the graft-
ersus-leukemia (GVL) effect [15]. The risk of relapse
ncreases signiﬁcantly when T cell-depleted grafts are
sed for transplantation [16]. Previous studies have
hown that the GVL effect can be preserved without
liciting a GVH reaction [17,18]; so targeted elimina- h
44ion of alloreactive T cells may prevent GVHD with-
ut losing the other beneﬁts of grafted T cells.
There are several approaches being investigated to
chieve selective allodepletion, including direct lysis
f in vitro activated alloreactive T cells via targeting of
urface markers or their elimination via cell sorting
19-29] or a combination of elimination and antipro-
iferative approaches, such as trimethrexate [30]. Some
f these approaches have been scaled up for clinical
rials, whereas others have remained preclinical, prob-
bly owing to very involved fractionation procedures.
hus, there is still the need for an effective but prac-
ical methodology that can achieve selective allodeple-
ion.
Methotrexate (MTX) is an FDA-approved drug
sed for the therapy of neoplastic diseases, rheumatoid
rthritis, and psoriasis. It is a folate analog that is
ctively transported into cells causing S-phase arrest
nd apoptosis. MTX chieﬂy inhibits the enzyme di-
ydrofolate reductase, which reduces dihydrofolate to
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Methotrexate for Selective Allodepletion 645etrahydrofolate. Importantly, MTX has been shown
o act on dividing T cells in vitro by interfering
ith DNA synthesis, repair, and cellular replication
31,32]. Based on this knowledge, we hypothesized
hat this drug may have the potential as an in vitro
gent of selective allodepletion. In this study, we eval-
ated this potential by studying the effects of MTX on
n vitro mixed lymphocyte reactions (MLRs). Using a
ensitive ﬂow cytometry-based system, we could char-
cterize the effect of MTX on both CD4 and CD8
cell proliferation and activation in primary MLRs,
s well as its utility in suppressing alloreactive re-
ponses in a speciﬁc manner. We present our preclin-
cal results from these assays to show that MTX has
xcellent potential as an in vitro allodepleting agent,
ffording a practical methodology that can be scaled
p for clinical use in the future.
ATERIALS AND METHODS
reparation and Isolation of Cells
Peripheral blood mononuclear cells (PBMCs)
rom random healthy donors were isolated from buffy
oats obtained from Carter Blood Care (Bedford,
X), using Ficoll-Paque Plus (GE Healthcare Bio-
ciences AB, Sweden). The study was approved by the
T Southwestern IRB and was performed on deiden-
iﬁed specimens from a blood donation center.
ixed Lymphocyte Reactions and Allodepletion
PBMCs were activated in 1-way MLRs under var-
ous conditions. Carboxyﬂuorescein diacetate succin-
midyl ester (CFSE)-based ﬂow cytometric prolifera-
ion assays were used, as described [33,34]. Brieﬂy,
FSE-stained PBMCs (responder cells) were suspended
n H5 medium (RPMI, Mediatech Inc., Herndon, VA,
% heat-inactivated human AB serum (Gemini Bio-
roducts West Sacramento, CA), and 1% mixture of
enicillin, streptomycin, and L-glutamine (Invitrogen
orp., Grand Island, NY) at a concentration of 106
ells/mL. Stimulator PBMCs from an HLA-mis-
atched random donor were irradiated (30 Gy) and
esuspended to the same concentration (of note, HLA
esting was not speciﬁcally performed on these spec-
mens, and thus, the degree of mismatch in each re-
ction was not known). These were mixed at a 1:1
atio of responders to stimulators and incubated in
-75 (75 cm2) tissue culture ﬂasks (BD Falcon, Lin-
oln Park, NJ) at 37°C in 5% CO2 for 7 days, unless
therwise indicated. In every experiment, an autolo-
ous reaction of CFSE-stained PBMCs and irradiated
BMCs from same donor served as a background
ontrol. This was an important control to ascertain
hat the MLRs observed were indeed alloantigen spe-
iﬁc. For positive proliferation controls, MLRs were timulated with 1 g/mL of the superantigen, staph-
lococcal enterotoxin B (SEB, Sigma, St. Louis, MO).
For experiments involving allodepletion, reactions
ere conducted in the presence (or absence) of 10 M
TX. For secondary MLRs, live cells were reisolated
rom the various primary reactions using Ficoll-Paque
radients. These cells were re-suspended in H5 me-
ium, rested for 2 days, and then rechallenged in a
econdary MLR. Cells from each primary reaction
ere stimulated in separate cultures with the follow-
ng stimuli: PBMCs from same responder (autologous
eaction), PBMCs from the same allostimulator as in
he primary MLR, PBMCs from an unrelated third
onor (“third party” stimulus), cytomegalovirus (CMV)
ntigen (Microbix Biosystems, Canada), or SEB. All
timulator cells were irradiated (30 Gy). These cul-
ures were conducted in 24-well plates (Greiner Bio-
ne, Monroe, NC) because of smaller cell numbers,
ith all other conditions remaining the same (cell
oncentrations, etc.). The secondary MLR cells were
arvested after 7 days and analyzed by ﬂow cytometry.
low Cytometry
In CFSE-based proliferation assays, dividing cells
re detected by sequential halving of their ﬂuores-
ence [35]. On the day of analysis, aliquots from
LRs were washed with FACS buffer (PBS with
% BSA and 0.1% sodium azide) and stained with
he following markers: anti-CD3-PerCP (peridinin
hlorophyll protein), anti-CD14-PE (phycoerythrin),
nti-CD4-PE Cy5.5 (phycoerythrin-cyanin5.5), anti-
D8-Paciﬁc Blue, and anti-CD25-APC (allophyco-
yanin) (antibodies from BD Biosciences, San Diego,
A, or Caltag Laboratories, Burlingame, CA). Cells
ere washed twice in FACS buffer and ﬁxed in 1%
araformaldehyde (Electron Microscopy Sciences,
atﬁeld, PA) containing 0.1% EDTA (Fisher, Fair-
ane, NJ). Flow cytometric data (at least 100,000 non-
ated events) were acquired on a BD FACS-Calibur
4-color) or on a BD LSR II multicolor ﬂow cytom-
ter using BD FACS Diva software. FlowJo (TreeStar
nc., Ashland, OR) or BD FACS Diva (BD Bio-
ciences) software were used for analysis. Cells were
ated on CD14/CD3 T cells and further on the
D4/CD8 or CD8/CD4 populations [33]. The
agnitude of proliferation was determined as the per-
entage of gated cells (CD4 or CD8) that were in the
roliferating fraction on the day of analysis. Back-
round proliferation was determined from the autolo-
ous MLR.
tatistical Analysis
Wilcoxon’s signed rank test was used to evaluate
uantitative differences between groups. A P value
.05 was considered signiﬁcant.
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A. Sathe et al.646ESULTS
ubject Characteristics
The median age of buffy coat donors was 26 years
range: 17-60 years). There were 11 male and 14
emale donors. Of 14 responder-stimulator pairs used
n MLRs, 10 donor pairs were gender matched (4
ale pairs and 6 female pairs) and 4 were gender
ismatched.
TX Inhibits Proliferation of Allogeneic CD4
nd CD8 T Cells in a Primary MLR with Little
ffect on T Cell Activation
Our ﬁrst step in the evaluation of MTX as an
llodepleting agent was to standardize culture condi-
ions for a primary MLR, using a CFSE-based prolif-
ration assay as a readout. In 5 replicate experiments,
e evaluated various cell ratios, cell concentrations,
nd culture times. Importantly, an autologous back-
round control was included in all our experiments to
scertain that the MLR readout was truly alloantigen
peciﬁc. We observed optimal reactions (signal:noise
iscrimination) at a ratio of 1:1 and a total cell con-
entration of 1  106/mL (optimization data not
hown). Across these experiments, a consistent kinetic
f activation and growth of T cells was observed (Fig-
re 1). On days 2 and 3 of the primary MLR, some
lloreactive proliferation was detected. However, this
rowth was not consistently greater than the small
mount of background proliferation present in au-
ologous controls. By day 5, proliferation in the
lloreaction increased markedly, and on day 7 of
ulture, alloreactive T cell proliferation was consis-
ently robust, compared to the autologous control.
his trend was similar for both CD4 and CD8 T
ells (Figure 1).
Once this consistent pattern was standardized, we
valuated the effect of MTX on primary MLRs. Var-
ous concentrations of MTX were used in initial ex-
eriments, based on prior literature, with optimal ef-
ect seen at 10 M. As expected, addition of MTX to
he alloreaction suppressed proliferation on all days,
nd this was most signiﬁcantly detected on days 5 and
of the culture (Figure 1B and C).
When measured on day 7 of culture in 14 replicate
xperiments (Figure 2), MTX treatment signiﬁcantly
nd consistently reduced CD4 T cell alloprolifera-
ion (proliferating fraction [PF] of 15.78%  4.86%
educed to 2.49%  0.65%, P  .001). Similarly, the
F of CD8 T cells was also signiﬁcantly reduced
rom 26.65%  7.3% to 1.72%  0.48%, P  .001.
here was no signiﬁcant difference between the au-
ologous background proliferation and the MTX-
reated alloreaction.
This effect of MTX was not restricted to the
lloreactions. In fact, the same concentration of MTX
obustly inhibited proliferation of CD4 and CD8T aells in superantigen-stimulated cultures (Figure 3).
hus, in vitro MTX treatment resulted in signiﬁcant
lockade of T cell proliferation.
In addition to proliferation, the ﬂow cytometric
ssay system also allowed to evaluate T cell activation
n these cultures, as indicated by upregulation of CD25
xpression. Interestingly, although MTX treatment had
dramatic effect on cell proliferation, it did not signiﬁ-
antly inhibit CD25 upregulation on the nondividing
D4 or CD8T cells, compared to the corresponding
opulation in the alloreaction (Figure 4). Of note,
hese did not simply represent preculture CD25 reg-
latory or activated T cells, as this population was
pregulated in the MLR, but not seen in the autolo-
ous control (data not shown). Thus, MTX was un-
ble to block initial activation of these cells, but clearly
locked their proliferation.
TX Treatment Results in Selective
llodepletion, with Preservation of Third-Party
nd Antiviral Responses
The results described above showed that MTX
ould inhibit the proliferation but not the initial acti-
ation of alloreactive T cells. The persistence of these
ells in the MLR cultures suggested that these cells
ay respond to the initial allostimulus once they were
reed from the antiproliferative inﬂuence of MTX, in
hich case “allodepletion” would not have been ac-
omplished.
To test this, we performed secondary MLRs using
ive cells obtained from the various primary MLRs
fter multiple washes. Thus, cells from the initial
onditions (autologous control, MLR, and MLR 
TX) were each exposed to different stimuli, includ-
ng autologous PBMCs, PBMCs from the initial allo-
timulus, PBMCs from a third-party allostimulus,
MV antigen, or SEB. In initial experiments, we
erformed a kinetic analysis, where cells were ob-
ained from primary MLRs that were cultured for 2, 3,
, and 7 days. Early cultures (days 2 and 3) showed
ittle or no effect on the secondary MLR proliferation
data not shown). Most optimal effects were observed
t 7 days of primary culture, and this time point was
icked for future experiments.
In 12 replicate experiments, we observed that both
D4 and CD8 T cells from the “MLR  MTX”
ondition failed to respond to the initial allostimulus,
hereas their response to a third-party stimulus, a
iral antigen, or a superantigen was intact (Figure 5).
hus, even after the cultures were freed of the anti-
roliferative action of MTX, the cells from the MTX-
reated alloreactions showed clear evidence of al-
odepletion. This was selective, as antiviral and
ntithird-party responses were preserved.
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Methotrexate for Selective Allodepletion 647igure 1. Kinetics of T cell growth in MLR and MTX blockade. (A) Representative dot plots of a primary MLR. CFSE staining is shown on
he X-axis and CD8 staining on Y-axis. The data are gated to show CD3/CD4/CD8 or CD3/CD4/CD8 cells; thus, the CD8
opulations represent CD4 T cells. The gray populations to the right represent nondividing cells. The dividing cells are shown in red (CD4
cells) and green (CD8 T cells). The numbers represent the proliferating fraction of CD4 and CD8 cells, respectively. As indicated, the
op row is an autologous control, the middle row is an alloreaction, and the bottom row is the SEB-stimulated positive control. Each column
epresents the indicated day of culture. Data is representative of 5 replicate experiments. The lower 2 panels show the percent proliferation
f CD4 (B) and CD8 (C) T cells at days 2, 3, 5, and 7 in an autologous control, an alloreaction, and an MTX-treated alloreaction. The mean
SEM) of 5 separate experiments is shown. Thus, MTX blocked the proliferation of both CD4 and CD8 T cells on all days.
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A. Sathe et al.648igure 2. Methotrexate inhibits proliferation of alloreactive T-cells. (A) Representative dot plots of an autologous reaction, an alloreaction,
nd an MTX-treated alloreaction at days 5 and 7 of culture. The layout is similar to that of Figure 1, with numbers representing CD4 and
D8 proliferation. Data is representative of 14 replicate experiments. (B, C) The cumulative data from the 14 experiments, represented as
ean  SEM of CD4 (B) and CD8 (C) T cell proliferation. MTX signiﬁcantly inhibited both CD4 and CD8 T cell proliferation in
rimary MLRs (P  .001).
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Methotrexate for Selective Allodepletion 649igure 3. Methotrexate suppresses proliferation of all dividing T-cells. (A) Representative dot plots demonstrating the proliferation of CD4
nd CD8 T cells in SEB-stimulated cultures in the presence (bottom row) or absence (top row) of MTX. (B, C) Cumulative data from 14
xperiments, demonstrating that MTX signiﬁcantly inhibited SEB-induced proliferation of both CD4 and CD8 T-cells.
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A. Sathe et al.650igure 4. Methotrexate does not affect activation of T cells in MLR. (A) Representative dot plots of CD25 expression on T cells on day 7 of
primary MLR in the presence (bottom row) or absence (top row) of MTX. CD4 T cells are shown in the left column, whereas CD8 T
ells are shown in the right column. CFSE staining is shown on the X-axis and CD25 staining on the Y-axis. The populations on the right
epresent nondividing cells. The threshold for CD25 expression was set using an isotype control antibody. The numbers represent the
ercentage of cells located in each quadrant. (B, C) Cumulative data from 14 replicate experiments. The graphs represent the mean (SEM)
ercentage of CD25/nondividing cells for the indicated culture conditions and cell types (n.s.  not signiﬁcant).
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Methotrexate for Selective Allodepletion 651igure 5. Methotrexate treatment of primary MLR results in selective allodepletion with preservation of third-party and antiviral responses.
A) Representative dot plots of a secondary MLR, using responder cells isolated from a primary alloreaction that was either untreated (top row)
r treated with MTX (bottom row) for 7 days. The stimulators were either the autologous control, the same allostimulus , a “third-party”
llostimulus, or CMV antigen (as indicated). (B, C) Cumulative data from 12 separate secondary MLRs. The mean proliferation (SEM) of
D4 (B) and CD8 (C) T cells are shown, under the indicated culture conditions. Thus, MTX treatment resulted in selective inhibition of
esponses to the same allostimulus, whereas leaving intact responses to third-party stimuli as well as a viral antigen.
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A. Sathe et al.652ISCUSSION
Pretransplant in vitro allodepletion is a feasible
ption to reduce the incidence and severity of GVHD.
n this study, we evaluated the potential use of meth-
trexate, an FDA-approved drug known to inhibit
cell proliferation, as an agent for speciﬁc in vitro
llodepletion. In previous studies, MTX was shown to
peciﬁcally kill/inhibit proliferating T cells. Addition-
lly, MTX was shown to inhibit T cells that prolifer-
te in response to a cell line and when these MTX-
reated cells were re-exposed to the same cell line,
hey did not show any response. In contrast, when
timulated with a different cell line these cells were
ctivated and responded by proliferating [36]. These
roperties of MTX suggest that it may be a suitable
nd practical agent for in vitro allodepletion. The po-
ential use of MTX for allodepletion has been suggested
n the past [37], but subsequent studies have been more
ocused on the role of MTX in autoimmune diseases,
specially rheumatoid arthritis [38,39]. Further rationale
or the use of MTX is provided by prior studies using
rimethrexate in combination with cell depletion ap-
roaches to achieve allodepletion [30].
In the current study, we used a sensitive ﬂow
ytometry-based proliferation assay to evaluate the
llodepleting potential of MTX. The multiparameter
ow cytometric approach allowed us to simulta-
eously measure proliferation and activation of both
D4 and CD8 T cell responses in a robust and
ell-controlled manner. This is a unique strength of
his study. Moreover, the careful standardization of
he assay, with the consistent inclusion of an autolo-
ous control adds speciﬁcity and conﬁdence to our
onclusions, as suggested by a recent study [40].
Using this assay system, we ﬁrst show that addi-
ion of MTX results in signiﬁcant inhibition of both
D4 and CD8 T cell proliferation in primary
LA-mismatched 1-way MLRs. In contrast, the ini-
ial activation of these T cells does not appear to be
ffected. However, we clearly demonstrate that these
TX-treated cells are unable to respond to the same
nitial allostimulus, consistent with allodepletion. This
uggests that the initially activated cells likely incor-
orate MTX during the primary exposure and are
nergic or undergo apoptosis during the re-exposure.
rior studies have demonstrated the ability of MTX
in contrast to several other immunosuppressive
gents) to induce apoptosis of alloreactive T cells [41],
nd this mechanism likely contributes in large part to
he lack of T cell response on re-exposure in our
ystem. Importantly, antiviral and third-party re-
ponses remain intact in the MTX-treated cells. Thus,
ur studies show that MTX is an effective agent of
elective in vitro allodepletion.
Although several strategies for in vitro allodeple-
ion have been proposed, their transition from pre- tlinical studies to clinical use is sometimes hindered
ecause of choice of reagent or technique. Several
llodepletion approaches use an activation marker
uch as CD69 or CD25 [23-28] for targeted elimina-
ion of alloreactive T cells. In an MLR, different
ctivation markers get preferentially upregulated at
arious time points, suggesting that different pathways
or activation are being used by alloantigen-speciﬁc
ells. Furthermore, all activated cells may not ex-
ress the marker(s) of interest at a given time point
29]. These ﬁndings can be explained by the hetero-
eneous nature of the in vitro alloresponse and sug-
est that if a single marker is used for targeted
limination of alloreactive T cells, it is likely that
ome alloreactive precursors may escape depletion.
llodepletion using multiple markers is likely to over-
ome this problem [29]. However, in addition to the
bovementioned activation markers, a large number of
ther markers like CD38, CD71, CD134, HLA-DR,
tc., are upregulated by the alloreactive cells at various
imes in an MLR [22]. In the absence of comprehen-
ive data determining the kinetics of expression and
pregulation of these molecules in an MLR, it would
e very difﬁcult to narrow down to 1 or 2 prospective
ctivation markers as being sufﬁcient for allodeple-
ion. Recent models of GVHD have shown that in
itro expansion of regulatory T cells (T regs) can
meliorate GVHD [42,43]. In humans, T regs are
istinguished by their CD4/CD25high/FOXP3
henotype. Allodepletion targeting CD25 as an acti-
ation marker may deplete this beneﬁcial cell popula-
ion. However, in MTX-based allodepletion, the pre-
ulture as well as induced T regs (as measured by
D25 and FOXP3 coexpression) are relatively pre-
erved (data not shown). Another drawback of cell
argeting methods is the potential elimination of by-
tander and memory cells that have low expression of
ctivation markers. This could reduce the available
ool of nonalloreactive but immunocompetent T cells
n the graft. As the action of MTX is speciﬁc for
ividing cells regardless of surface phenotype, MTX-
ased allodepletion can steer clear of these problems.
Even though our ﬁndings demonstrate the poten-
ial of MTX for in vitro allodepletion, there are ad-
ittedly some drawbacks. First, MTX-based deple-
ion is dependent on early and vigorous proliferation
f alloreactive cells in an MLR. As MTX acts by
locking the folate pathway, unless the alloreactive T
ell begins folate uptake and initiates cell division, it
annot be eliminated from the primary MLR. Thus,
eak or delayed proliferation of T cells may lead to
ess efﬁcient depletion of the alloreactive cells. This
roblem may be of more concern in an HLA-matched
etting (or potentially in a haploidentical or locus-
ismatched situations) because of potentially weaker
r delayed proliferation. In ensuing studies, we intend
o directly address this issue. Second, our study deter-
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Methotrexate for Selective Allodepletion 653ined that it was necessary to culture a primary MLR
or 5-7 days to ensure and maximize allodepletion by
TX (data not shown). A shorter period of culture
ay be more attractive clinically, but the variable pro-
iferation at earlier time points meant that all alloreactive
recursors were not actively dividing and MTX could
ot inhibit/eliminate them. However, this may be a mi-
or concern as a 7-day culture can still be envisaged in
he clinical setting. In our opinion, the advantages af-
orded by this agent appear to override the drawbacks,
aking it an attractive target for future studies.
In conclusion, our results provide strong preclin-
cal evidence that in vitro treatment with MTX, a
ractical FDA-approved agent, results in speciﬁc al-
odepletion and may have excellent potential as an
ffective approach for preventing or minimizing
VHD.
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